Herborium Provides Editorial on Natural Acne Treatment for U.K.'s National Primary Care Review
December 22 2010 - 10:30AM
Marketwired
Herborium Group, Inc., (PINKSHEETS: HBRM), a Botanical
Therapeutics™ company (www.herborium.com), today announced that it
has been selected to provide the editorial on alternative acne
treatment for National Association of Primary Care (NAPC) Review,
Spring 2011 edition.
"Exposure in such a prestigious medical review to
tens-of-thousands of U.K. general practitioners and dermatologists
is a significant boost in Herborium's European brand building
efforts, as well as promising acceleration of sales; it also
advances the company's goal to become the worldwide leader in
natural medicine," commented Dr. Agnes P. Olszewski, Herborium's
president and chief executive officer. "The Review is distributed
to 36,000 general practitioners and almost 2,000 dermatologists and
dermatological groups."
The high-profile exposure comes at a most advantageous time, as
AcnEase, (www.acnease.com) Herborium's all botanical, clinically
tested acne and Rosacea treatment continues to grow as the
treatment of choice in the U.K. and EU. Since general practitioners
and dermatologists can operate their own pharmacies on premises and
sell both prescriptive drugs as well as supplements, and natural
medicines Herborium expects a further growth in sales as a result
of the Editorial.
Currently, the only class of FDA approved drug to treat the
cause of acne is isotretinoin. Manufactured by Hoffman La-Roche and
marketed under the trade name Accutane in the U.S., and Roaccutane
in Europe, this drug class was recently taken off the market due to
the high number of severe side effects and the pending class-action
lawsuits.
AcnEase represents a safe, effective, and natural alternative
for treatment and prevention of acne.
The Spring 2011 edition of The NAPC Review is solely devoted to
Acne etiology and treatments and is co-sponsored by the British
Skin Foundation and the British Association of Dermatologists. The
NAPC Review is sent to every General Practitioner and every
Dermatologist in Great Britain effectively covering all doctors who
treat patients with acne and Rosacea. Herborium's clinically tested
botanical acne medicine, AcnEase, currently being sold in the U.K.
since 2004, was cited as a reason for Herborium's selection.
About Herborium Group, Inc. Herborium
Group, Inc., a Botanical Therapeutics® company, focuses on
developing, licensing, and marketing proprietary, botanically based
medicinal products to consumers and healthcare professionals. The
Company's business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses clinical
validation and a proactive regulatory strategy based on the FDA
Guidance for Industry: Botanical Drug Products (FDA Guidance 2004)
to establish and maintain a differential advantage. For more
information, please visit www.herborium.com and
www.acnease.com.
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time they are issued, and we disclaim any
obligation to update or alter forward-looking statements as the
result of new information or future events. The Company urges
investors to review the risks and uncertainties contained within
its filings with the OTC Markets and/or Securities and Exchange
Commission.
Company Contact: Steve Haag Investor Relations (832)
413-6206
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Sep 2024 to Oct 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Oct 2023 to Oct 2024